Preferred Label : Garetatug Rezetecan;
NCIt synonyms : ADC SHR-A1904; Anti-CLDN18.2 ADC SHR-A1904; Anti-CLDN18.2 Antibody-drug Conjugate SHR-A1904; Anti-Claudin 18.2 ADC SHR-A1904; Anti-Claudin 18.2 Antibody-drug Conjugate SHR-A1904;
NCIt definition : An antibody-drug conjugate (ADC) composed of garetatug, an immunoglobulin G1 (IgG1)
monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin 18.2
(CLDN18.2; A2 isoform of claudin-18) conjugated, via a cleavable linker, to rezetecan,
an exatecan derivative and topoisomerase 1 inhibitor, with potential antineoplastic
activity. Upon administration of garetatug rezetecan, the anti-CLDN18.2 monoclonal
antibody moiety specifically targets and binds to CLDN18.2 expressed on tumor cells.
Upon binding, internalization and linker cleavage, rezetecan is released and inhibits
DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in
cell cycle arrest and apoptosis in tumor cells expressing CLDN18.2. CLDN18.2, a tight
junction protein and stomach-specific isoform of claudin-18, is expressed on a variety
of tumor cells. Its expression in healthy tissues is strictly confined to short-lived
differentiated epithelial cells of the gastric mucosa.;
UNII : FD5J5RLD4E;
CAS number : 3023285-06-2;
Molecule name : SHR A1904; SHR-A1904;
NCI Metathesaurus CUI : CL1663598;
Origin ID : C181025;
UMLS CUI : C5556789;
Semantic type(s)
- concept_is_in_subset
- has_target
